Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed (IPPEM)

June 20, 2018

Primary Outcome Measures

Association between PPI consumption and pemetrexed-related hematological toxicity (grade ≥ 3) [ Time Frame: Day 0 ]
The hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria

Eligibility Criteria

Inclusion Criteria: Patients who receive a pemetrexed-based chemotherapy regimen for the treatment of non-small cell lung cancer (NSCLC) or mesothelioma,; Patients who consent to participate,; Patients for whom it is possible to characterize the consumption of proton pump inhibitors with name of the PPI

Exclusion Criteria: Patients who receive pemetrexed out of intravenous of for another condition than NSCLC or mesothelioma; Patients under 18 or who refused the participation in the data collection,; Patient previously treated by a pemetrexed-based chemotherapy,; Patients who first receive a pemetrexed-based regimen with an initial dose adjustment (<500 mg/m²) and dosage.

CONTACT INFORMATION

Name*

First Last

Email*

Phone*

Address*

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Have you received a diagnosis?*

Yes

DIAGNOSIS

Diagnosis?*

Date of Diagnosis*

Comments*

Phone

This field is for validation purposes and should be left unchanged.

Quick Facts

Accepts Healthy Volunteers
Ages Available for Study
ClinicalTrials.gov Identifier
Collaborators
Contacts(s)
Location(s)
Estimated Enrollment
Estimated Study Start Date
Estimated Primary Completion Dates
Full Title
Genders Eligible for Study
Investigator(s)
Last Updated
Other Contact